Imexpharm Past Earnings Performance
Past criteria checks 5/6
Imexpharm has been growing earnings at an average annual rate of 13.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 8.7% per year. Imexpharm's return on equity is 14.4%, and it has net margins of 12.8%.
Key information
13.7%
Earnings growth rate
12.7%
EPS growth rate
Pharmaceuticals Industry Growth | 13.0% |
Revenue growth rate | 8.7% |
Return on equity | 14.4% |
Net Margin | 12.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Imexpharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,994,037 | 254,623 | 604,588 | 0 |
30 Sep 23 | 1,943,044 | 258,089 | 610,705 | 0 |
30 Jun 23 | 1,893,973 | 244,173 | 612,313 | 0 |
31 Mar 23 | 1,808,733 | 213,197 | 577,769 | 0 |
31 Dec 22 | 1,643,707 | 196,715 | 523,055 | 0 |
30 Sep 22 | 1,483,063 | 193,294 | 435,563 | 0 |
30 Jun 22 | 1,321,432 | 168,823 | 393,080 | 0 |
31 Mar 22 | 1,284,405 | 176,146 | 373,975 | 0 |
31 Dec 21 | 1,266,597 | 173,513 | 362,868 | 0 |
30 Sep 21 | 1,357,095 | 173,320 | 398,646 | 0 |
30 Jun 21 | 1,390,894 | 192,894 | 404,511 | 0 |
31 Mar 21 | 1,362,172 | 184,242 | 372,334 | 0 |
31 Dec 20 | 1,369,422 | 179,658 | 356,763 | 0 |
30 Sep 20 | 1,398,480 | 164,014 | 380,731 | 0 |
30 Jun 20 | 1,436,011 | 154,636 | 399,044 | 0 |
31 Mar 20 | 1,432,983 | 145,354 | 423,344 | 0 |
31 Dec 19 | 1,402,454 | 142,900 | 436,016 | 0 |
30 Sep 19 | 1,261,051 | 131,865 | 404,685 | 0 |
30 Jun 19 | 1,230,077 | 125,694 | 399,740 | 0 |
31 Mar 19 | 1,204,780 | 124,885 | 408,609 | 0 |
31 Dec 18 | 1,184,818 | 122,041 | 387,177 | 0 |
30 Sep 18 | 1,224,760 | 112,394 | 415,007 | 0 |
30 Jun 18 | 1,178,882 | 106,176 | 402,224 | 0 |
31 Mar 18 | 1,194,327 | 109,745 | 408,690 | 0 |
31 Dec 17 | 1,165,456 | 103,277 | 415,329 | 0 |
30 Sep 17 | 1,116,855 | 110,222 | 442,738 | 0 |
30 Jun 17 | 1,081,387 | 104,160 | 444,487 | 0 |
31 Mar 17 | 1,041,967 | 90,389 | 419,288 | 0 |
31 Dec 16 | 1,010,346 | 88,009 | 372,132 | 0 |
30 Sep 16 | 979,587 | 75,696 | 231,341 | 0 |
30 Jun 16 | 948,208 | 70,215 | 209,275 | 0 |
31 Mar 16 | 941,857 | 78,639 | 261,529 | 0 |
31 Dec 15 | 964,319 | 81,760 | 265,938 | 0 |
30 Sep 15 | 935,085 | 81,196 | 326,394 | 0 |
30 Jun 15 | 968,853 | 84,855 | 362,380 | 0 |
31 Mar 15 | 937,561 | 76,918 | 305,263 | 0 |
31 Dec 14 | 897,136 | 72,933 | 310,356 | 0 |
30 Sep 14 | 825,305 | 53,276 | 285,242 | 0 |
30 Jun 14 | 809,110 | 51,677 | 273,447 | 0 |
31 Mar 14 | 830,007 | 55,051 | 278,591 | 0 |
31 Dec 13 | 841,316 | 60,624 | 290,306 | 0 |
30 Sep 13 | 863,000 | 73,279 | 288,010 | 0 |
30 Jun 13 | 862,483 | 75,840 | 292,704 | 0 |
31 Mar 13 | 830,187 | 76,835 | 279,580 | 0 |
Quality Earnings: IMP has high quality earnings.
Growing Profit Margin: IMP's current net profit margins (12.8%) are higher than last year (12%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMP's earnings have grown by 13.7% per year over the past 5 years.
Accelerating Growth: IMP's earnings growth over the past year (29.4%) exceeds its 5-year average (13.7% per year).
Earnings vs Industry: IMP earnings growth over the past year (29.4%) exceeded the Pharmaceuticals industry -3.6%.
Return on Equity
High ROE: IMP's Return on Equity (14.4%) is considered low.